These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 37993332)

  • 1. Preclinical evaluation of RQ3013, a broad-spectrum mRNA vaccine against SARS-CoV-2 variants.
    Tan S; Zhao J; Hu X; Li Y; Wu Z; Lu G; Yu Z; Du B; Liu Y; Li L; Chen Y; Li Y; Yao Y; Zhang X; Rao J; Gao G; Peng Y; Liu H; Yuan Z; Liu J; Wang Q; Hu H; Gao X; Zhou H; Yu H; Xu Y; Yu W; Feng L; Wang M; Shan C; Lu J; Lin J
    Sci Bull (Beijing); 2023 Dec; 68(24):3192-3206. PubMed ID: 37993332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.
    Zhang Y; Ma X; Yan G; Wu Y; Chen Y; Zhou Z; Wan N; Su W; Liu FW; Dai MX; Yang M; Li C; Yu X; Zhang L; Wang Z; Zhou TC; You D; Wei J; Zhang Z;
    EClinicalMedicine; 2022 Dec; 54():101680. PubMed ID: 36188435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA Vaccine Mitigates SARS-CoV-2 Infections and COVID-19.
    Kackos CM; Surman SL; Jones BG; Sealy RE; Jeevan T; Davitt CJH; Pustylnikov S; Darling TL; Boon ACM; Hurwitz JL; Samsa MM; Webby RJ
    Microbiol Spectr; 2023 Feb; 11(1):e0424022. PubMed ID: 36695597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.
    Liu J; Budylowski P; Samson R; Griffin BD; Babuadze G; Rathod B; Colwill K; Abioye JA; Schwartz JA; Law R; Yip L; Ahn SK; Chau S; Naghibosadat M; Arita Y; Hu Q; Yue FY; Banerjee A; Hardy WR; Mossman K; Mubareka S; Kozak RA; Pollanen MS; Martin Orozco N; Gingras AC; Marcusson EG; Ostrowski MA
    Sci Adv; 2022 Jan; 8(3):eabj9815. PubMed ID: 35044832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies.
    Lu J; Tan S; Gu H; Liu K; Huang W; Yu Z; Lu G; Wu Z; Gao X; Zhao J; Yao Z; Yi F; Yang Y; Wang H; Hu X; Lu M; Li W; Zhou H; Yu H; Shan C; Lin J
    Emerg Microbes Infect; 2024 Dec; 13(1):2321994. PubMed ID: 38377136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial.
    Liu X; Sun Z; Wang Z; Chen J; Wu Q; Zheng Y; Yang X; Mo L; Yan X; Li W; Zou Y; Song H; Qian F; Lu J; Zhou H; Wang Y; Xiang Z; Yu H; Lin J; Yuan L; Zheng Y
    EClinicalMedicine; 2023 Oct; 64():102231. PubMed ID: 37767190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.
    Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH
    J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern.
    Ma Q; Li M; Ma L; Zhang C; Zhang H; Zhong H; Wen J; Wang Y; Yan Z; Xiong W; Wu L; Guo J; Yang W; Yang Z; Zhang B
    Front Immunol; 2023; 14():1195299. PubMed ID: 37292197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
    J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.
    Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J
    J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine.
    Wu Y; Wang S; Zhang Y; Yuan L; Zheng Q; Wei M; Shi Y; Wang Z; Ma J; Wang K; Nie M; Xiao J; Huang Z; Chen P; Guo H; Lan M; Xu J; Hou W; Hong Y; Chen D; Sun H; Xiong H; Zhou M; Liu C; Guo W; Guo H; Gao J; Gan C; Li Z; Zhang H; Wang X; Li S; Cheng T; Zhao Q; Chen Y; Wu T; Zhang T; Zhang J; Cao H; Zhu H; Yuan Q; Guan Y; Xia N
    Cell Host Microbe; 2022 Dec; 30(12):1732-1744.e7. PubMed ID: 36323313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circular RNA vaccines against SARS-CoV-2 and emerging variants.
    Qu L; Yi Z; Shen Y; Lin L; Chen F; Xu Y; Wu Z; Tang H; Zhang X; Tian F; Wang C; Xiao X; Dong X; Guo L; Lu S; Yang C; Tang C; Yang Y; Yu W; Wang J; Zhou Y; Huang Q; Yisimayi A; Liu S; Huang W; Cao Y; Wang Y; Zhou Z; Peng X; Wang J; Xie XS; Wei W
    Cell; 2022 May; 185(10):1728-1744.e16. PubMed ID: 35460644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines.
    Sun C; Yuan RY; Xie C; Sun JF; Fang XY; Hu YS; Yu XH; Liu Z; Zeng MS; Kang YF
    J Virol; 2022 Jul; 96(13):e0038322. PubMed ID: 35699445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters.
    de Moor WRJ; Williamson AL; Schäfer G; Douglass N; Gers S; Sutherland AD; Blumenthal MJ; Margolin E; Shaw ML; Preiser W; Chapman R
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
    Collier AY; McMahan K; Yu J; Tostanoski LH; Aguayo R; Ansel J; Chandrashekar A; Patel S; Apraku Bondzie E; Sellers D; Barrett J; Sanborn O; Wan H; Chang A; Anioke T; Nkolola J; Bradshaw C; Jacob-Dolan C; Feldman J; Gebre M; Borducchi EN; Liu J; Schmidt AG; Suscovich T; Linde C; Alter G; Hacker MR; Barouch DH
    JAMA; 2021 Jun; 325(23):2370-2380. PubMed ID: 33983379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monovalent SARS-COV-2 mRNA vaccine using optimal UTRs and LNPs is highly immunogenic and broadly protective against Omicron variants.
    Ye Z; Bonam SR; McKay LGA; Plante JA; Walker J; Zhao Y; Huang C; Chen J; Xu C; Li Y; Liu L; Harmon J; Gao S; Song D; Zhang Z; Plante KS; Griffiths A; Chen J; Hu H; Xu Q
    Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2311752120. PubMed ID: 38134199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.